https://de.marketscreener.com/kurs/aktie/INCYTE-CORPORATION-9675/news/Incyte-und-MorphoSys-melden-Dreijahresergebnisse-aus-der-Phase-2-Studie-L-MIND-zu-Tafasitamab-in-K-35531377/?utm_source=telegram&utm_medium=social&utm_campaign=share